about
Animal Models to Study Links between Cardiovascular Disease and Renal Failure and Their Relevance to Human PathologyRelaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2SELDI-TOF mass spectrometry-based protein profiling of kidney tissue.Epigenetic Modifications to H3K9 in Renal Tubulointerstitial Cells after Unilateral Ureteric Obstruction and TGF-β1 StimulationSoluble klotho may be a marker of phosphate reabsorption.FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.The role of tubulointerstitial injury in chronic renal failure.A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum.Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.Development of second generation peptides modulating cellular adiponectin receptor responses.Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.Pharmacological intervention in renal fibrosis and vascular sclerosis.Laser Capture Microdissection of Archival Kidney Tissue for qRT-PCR.Qualitative and Quantitative Analysis of Histone Deacetylases in Kidney Tissue Sections.Fibrosis in the kidney: is a problem shared a problem halved?Relaxin in cardiovascular and renal disease.In situ hybridization using cRNA probes: isotopic and nonisotopic detection methods.Histochemical localization of cell proliferation using in situ hybridization for histone mRNA.Histochemical localization of apoptosis with in situ labeling of fragmented DNA.Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice.Interstitial myofibroblasts in IgA glomerulonephritis.The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.Relaxin and the progression of kidney disease.Renal tubulointerstitial fibrosis: common but never simple.Small animal models of kidney disease: a review.Changes in Markers of Mineral Metabolism After Living Kidney Donation.Hypoxia and hypoxia signaling in tissue repair and fibrosis.Therapeutic effects of serelaxin in acute heart failure.The importance of klotho in phosphate metabolism and kidney disease.The Role of Secondary Calciprotein Particles in the Mineralisation Paradox of Chronic Kidney Disease.Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.Antifibrotic Actions of Serelaxin - New Roles for an Old Player.Anti-fibrotic actions of relaxin.Hypoxia in tissue repair and fibrosis.Explanting is an ex vivo model of renal epithelial-mesenchymal transition.Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype - Role of Risk Factors and Epigenetics.Dipyridamole inhibits in vitro renal fibroblast proliferation and collagen synthesis.Aberrant protein expression in plasma and kidney tissue during experimental obstructive nephropathy.Aldosterone in clinical nephrology--old hormone, new questions.FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction.
P50
Q26781300-FD25A549-A5C9-453B-A22F-C2CFC2573AF3Q28507233-77149BCD-9D93-41C6-B282-B16BEDE1DAE8Q33400404-DECA369A-0D42-4548-B8FC-E7C6FC4154C1Q33734913-6DF97BD0-DAB7-4541-9117-B1472D0CBD67Q33783120-61CD9E53-3E61-4FD1-9A37-4A1146236DDBQ33793927-4FC44DAA-C68D-4E2F-8BBB-DCEC961C7726Q33886665-5DB3D788-D902-4DA9-9AA9-8E8E29655A43Q33916132-013916E4-CD7C-4B38-8FD5-F144F42D82BDQ34108717-64F174EF-F7B1-4CAF-86AE-5CEA4A4D6B34Q34360125-8482C9F3-F852-4A1B-ADFE-C0F0266A1C95Q34398874-D18F714A-1838-44E4-B699-603286F69FDEQ34454815-C73C5130-D585-4A9C-9571-72D9448FABBBQ35871079-9C6B5148-5422-46D7-89D1-5B1B11EC41EFQ35871084-991FF16E-8B91-4765-8FA4-19CDF8421D78Q36012555-71AA3F67-656D-4B8F-BF57-6D56235F8DEDQ36467817-144E10E3-853C-40EA-99C2-924CA30517A9Q36509111-6137AA99-62F3-4ECE-B123-95177B8B0F10Q36509167-637EC3C2-6EB6-4139-942D-EA6BA4D1CF6DQ36509171-E80F91B7-291F-4773-B8F9-32A1C76BECBFQ36546979-B8102A9A-1A2B-4F44-8FB2-F47DC4563763Q36702090-C19AEFBD-23D7-472B-BF04-E25EAEA4EE57Q36749450-5E5F0626-8356-4C4B-A4B4-F642C34F62A9Q37349029-1A3EE8C6-CB3F-4B8F-9030-4D778DCAC901Q37368710-40642EF9-01E8-4345-ACD8-4443F5EE105FQ37369960-BE0DA0B5-506F-4E57-8078-5E32BADD3898Q37738753-C8D9E29C-BF9B-4FD4-B787-A03D97AE8E2FQ38007604-36DAEC72-B53F-47A2-9ECF-277E521865AAQ38180883-5725E84A-E3F5-481D-8654-83A6F45DBFE1Q38205938-E5593A32-CABE-41D0-9A3E-CAC14ABC514BQ38693604-AA5C3A1A-3A32-469B-8B83-FF7F42EEC7C8Q38781702-A7F3EC8A-BCE4-4BC2-ABD4-0E423962C3BBQ38782256-EACCF368-BEDB-4A03-89C9-E7E20A3EBC55Q38850557-EAA4C6E4-82D7-4EA8-8F4E-EE2F7EC4E442Q38898935-3B8BC8A8-819B-444C-B5CD-D9B20CF0B0ECQ39488790-9E9E5342-04D0-4BFF-B411-24139A16A8D2Q41333737-29DAC475-81D9-44AB-BD5E-2D8CEA7B5EF2Q42526243-F41F89CD-CBD2-44FA-924F-8FD481AC2901Q42784818-D0AD3972-96DE-4D9D-8713-0A62885791B6Q45983816-66F2B0FC-C1FD-4900-9E40-DFEBA51948CAQ46305703-68472270-BCB7-4834-BDC9-94283259405F
P50
description
researcher
@en
wetenschapper
@nl
name
T D Hewitson
@ast
T D Hewitson
@en
T D Hewitson
@nl
type
label
T D Hewitson
@ast
T D Hewitson
@en
T D Hewitson
@nl
prefLabel
T D Hewitson
@ast
T D Hewitson
@en
T D Hewitson
@nl
P106
P31
P496
0000-0002-1994-2423